STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads

STAT PlusPharmalot FDA is urged by advocacy group to ban DTC prescription drug ads Public Citizen argues the ads often ‘mislead consumers because they are designed to persuade,’ not inform or educate Manage alerts for this article Email this article Share this article By Ed SilvermanJuly 23, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. A leading advocacy group petitioned the U.S. Food and Drug Administration to ban direct-to-consumer advertising of prescription medicines, a move that comes as the Trump administration leans on drugmakers to provide more balanced information in their ads. In arguing its case, Public Citizen maintained that director-to-consumer, or DTC, ads often “mislead consumers because they are designed to persuade rather than to inform or educate patients.” The ads sometimes “employ emotional manipulation techniques or visual distractions to highlight information about benefits” while minimizing risks.Advertisement The advocacy group hopes to persuade the FDA after the Trump administration last September announced a “crackdown” on what it called deceptive drug advertising. At the time, the administration disclosed plans for new rules and stronger enforcement, which was followed by dozens of letters sent to companies regarding problems with their ads. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In FDA, Pharmaceuticals, Policy, public health, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot July 23, 2026 STAT Plus: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more Pharmalot July 22, 2026 STAT Plus: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more Advertisement Pharmalot July 21, 2026 STAT Plus: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more Pharmalot July 21, 2026 STAT Plus: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’ Pharmalot July 20, 2026 STAT Plus: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and more Subscriber Picks